Kleberg Foundation

A new method speeds the analysis of factors that control gene expression from days to minutes, allowing researchers to uncover new targets for cancer treatment. Read More

William Tansey and colleagues identified proteins that interact with the cancer drug target WDR5 and are important for cancer cell growth. Read More

Elevated levels of the factor G-CSF appear to promote the development of aggressive pancreatic cancer, suggesting a new therapeutic approach for this devastating disease. Read More

The histone deacetylase HDAC3 is required for the maturation of B cells, white blood cells that produce antibodies. Read More

A PET probe that detects the amino acid glutamine predicts whether tumors respond to certain targeted therapies in preclinical animal models. Read More

The Robert J. Kleberg Jr. and Helen C. Kleberg Foundation has awarded a $3 million grant to Vanderbilt-Ingram Cancer Center (VICC) investigators in support of VICC’s drug discovery program. The gift awarded over the next three years from the private, San Antonio, Texas-based foundation will enable VICC researchers to pursue the development of new compounds to block the activity of cancer-causing genes and proteins that had previously been considered “undruggable.” Read More

Combining inhibitors of the BMP signaling pathway with standard chemotherapy drugs may overcome drug resistance in ovarian cancer. Read More

Inhibition of BMP growth factor signaling reduces breast tumor burden and metastasis. Read More

A novel PET imaging probe detects tumor cell death in vivo and could be useful for personalizing cancer medicine. Read More